Every Form 4 that Telomir Pharmaceuticals, Inc. (TELO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TELO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELO filings page.
Telomir Pharmaceuticals director Whalen Matthew Pratt received a grant of 50,000 Non-Qualified Stock Options on April 16, 2026. The options have an exercise price of $1.3400 per share, expire on April 16, 2036, were granted under the 2023 Omnibus Incentive Plan, vested immediately, and leave him holding 50,000 derivative securities directly.
Telomir Pharmaceuticals, Inc. reported that director Edward Clouston MacPherson received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, vested immediately, expire on April 16, 2036, and represent 50,000 options held directly after the grant.
Telomir Pharmaceuticals, Inc. reported that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, equal to the closing price that day, and vested immediately upon issuance. They are exercisable for common stock and expire on April 16, 2036, resulting in Del Giudice holding 50,000 options after the grant, awarded under the company’s 2023 Omnibus Incentive Plan. The transaction was not made under a Rule 10b5-1 trading plan.
Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov reported changes to his stock option awards. On May 21, 2026, he agreed to cancel previously granted options for 2,000,000 shares of common stock at a $2.10 exercise price and 1,960,170 shares at $5.02, both through dispositions to the issuer. In exchange, he received fully exercisable new options covering the same share amounts at a lower $1.30 exercise price, with expirations in 2036. The filing also shows he holds 7,319,710 common shares directly after these transactions, and it does not report any open‑market purchases or sales.
Telomir Pharmaceuticals director Whalen Matthew Pratt reported an option restructuring. He agreed to cancel 25,000 incentive stock options with a $5.02 exercise price in exchange for 25,000 new options with a lower $1.30 exercise price, expiring on May 21, 2036. Following these transactions, he holds 25,000 incentive stock options that are fully exercisable.
Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options with no net change in option count. He agreed to cancel an existing option for 25,000 shares of common stock with a $5.02 exercise price and an expiration on August 27, 2034. In exchange, he received a new option for 25,000 shares at a lower exercise price of $1.30, expiring on May 21, 2036. These are incentive stock options granted as compensation, not open-market share purchases or sales, and he now holds 25,000 options directly following the transaction.
Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count. He agreed to cancel 25,000 fully exercisable incentive stock options for common stock with a $5.02 exercise price and a August 27, 2034 expiration, as a disposition back to the issuer.
In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market.
Telomir Pharmaceuticals CEO and Chairman Erez Aminov reported a restructuring-related share exchange rather than an open-market trade. He is shown with 7,319,710 shares of common stock at a reported value of $1.3700 per share following the transaction. A footnote explains these Telomir shares were issued to him in exchange for his shares of TELI Pharmaceuticals, Inc. in connection with Telomir’s acquisition of TELI, so the filing reflects how his prior TELI ownership converted into Telomir equity.